Skip to main content
. 2022 Mar 23;13:822615. doi: 10.3389/fphar.2022.822615

FIGURE 1.

FIGURE 1

Olmesartan (Olm) can attenuate single-lung ventilation (SLV) induced lung injury. Lung histopathological alterations in rats in the S (sham) group; AS (ARB + sham) group, in which the rats given 7 days Olm treatment before the sham surgery; I (injury) group, in which the rats underwent SLV for 1 h (right lung ventilation and left lung collapsed) and double lungs ventilation for 3 h; and the AI (ARB + injury) group (hematoxylin and eosin staining; original magnification, ×400) (n = 6) (A). The lung injury score of HE staining in rats in each group (B). Lung W/D ratio in rats in all groups (C). IL-6 in plasma as shown by ELISA (D). Quantitative analysis of IL-6, IL-1β and TNF-α in HUVECs culture supernatant in different groups by ELISA (E–G) (n = 3). Quantitative analysis of IL-6, IL-1β and TNF-α in A549 cell culture supernatant by ELISA (H–J) (n = 3). Data are presented as the mean ± standard error of the mean. NS: not significantly different. *p < 0.05, **p < 0.005, ***p < 0.001, ****p < 0.0001. SLV: single-lung ventilation; Olm: olmesartan; ARB: angiotensin receptor blocker; S: sham; AS: ARB + sham; I: injury; AI: ARB + injury; Ctr: control; IR: ischemia reperfusion; W/D: wet/dry ratio; IL-6: interleukin-6; IL-1β: interleukin-1β; TNF-α: tumor necrosis factor-α; ELISA: Enzyme-linked immunosorbent assay.